7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(3-chloro-6-methoxypyridin-2-ylamino)-5-isopropoxyquinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(3-chloro-6-methoxypyridin-2-ylamino)-5-isopropoxyquinazoline
• 英文别名: 1-[4-[2-[4-[(3-chloro-6-methoxypyridin-2-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanone
• 化学式: C₂₅H₃₁ClN₆O₄
• 分子量: 515.012
• InChiKey: GEPQBTPKIOBUQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5,7-二氟-3,4-二氢喹唑啉-4-酮 在 potassium tert-butylate 、 sodium hexamethyldisilazane 、 sodium hydride 、 potassium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 potassium iodide 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(3-chloro-6-methoxypyridin-2-ylamino)-5-isopropoxyquinazoline
  参考文献：
  名称：

  New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors

  摘要：

  A series of 5,7-disubstituted quinazolines, bearing 4-heteroaryl substituents such as 2-pyridinylamine or 2-pyrazinylamine, has been synthetised and evaluated as c-Src kinase inhibitors. Highly potent inhibition, high selectivity and physical properties suitable for oral dosing were achieved within this series: 23d and 42 were identified as sub-0.1 mu M inhibitors in a c-Src-driven cell proliferation assay and displayed adequate rat pharmacokinetics after oral administration. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.106

文献信息

• New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors
  作者：Bernard Barlaam、Mike Fennell、Hervé Germain、Tim Green、Laurent Hennequin、Rémy Morgentin、Annie Olivier、Patrick Plé、Michel Vautier、Gerard Costello

  DOI：10.1016/j.bmcl.2005.08.106

  日期：2005.12

  A series of 5,7-disubstituted quinazolines, bearing 4-heteroaryl substituents such as 2-pyridinylamine or 2-pyrazinylamine, has been synthetised and evaluated as c-Src kinase inhibitors. Highly potent inhibition, high selectivity and physical properties suitable for oral dosing were achieved within this series: 23d and 42 were identified as sub-0.1 mu M inhibitors in a c-Src-driven cell proliferation assay and displayed adequate rat pharmacokinetics after oral administration. (c) 2005 Elsevier Ltd. All rights reserved.